Skip to main content

Table 4 Clinical factors for renal function decrease

From: Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients

Patient Group D
13 (37.5%)
Group ND
27 (62.5%)
p-value
[background factors]
 Age, median [range] 66 [46–76] 69 [33–78] 0.1650
 Sex, male (%) 2 (15.4) 11 (40.7) 0.0951
 BW (kg), median [range] 57.9 [41.6–74.0] 60.7 [35.3–97.1] 0.4356
 Histopathology, follicular (%) 5 (38.4) 10 (37.0) 0.9306
 Performance status, ≥ 1 6 (46.5%) 11 (40.7%) 0.7460
 eGFR at baseline (mL/min/1.73 m2), median [range] 78.5 [65.2–118.7] 63.8 [43.6–119.1] 0.0165
 eGFR at baseline (mL/min/1.73 m2), < 60 0 (0) 8 (29.6) 0.0072
 Proteinuria grade 1 at baseline, yes (%) 2 (15.4) 0 (0) 0.0298
 Past hypertension history (%) 8 (61.5) 16 (59.3) 0.8903
 Past diabetes mellitus history (%) 1 (7.7) 2 (7.4) 0.9745
 Past renal history (%) 1 (7.7) 5 (18.5) 0.3452
 Renal metastasis, (%) 0 (0) 3 (11.1) 0.1158
 Liver metastasis, (%) 1 (7.7) 6 (22.2) 0.2296
[Treatment-related factors]
 Treatment period (months) 34.1 [12.8–60.5] 25.2 [6.8–61.5] 0.0832
 Observation period (months) 45.4 [21.0–60.5] 27.2 [7.4–61.5] 0.0115
 Dose intensity (mg/day), median [range] 9.7 [4.1–14.0] 9.46 [4.0–16.4] 0.7398
 Best response in RECIST criteria, PR (%) 10 (76.9) 19 (70.4) 0.6606
 Proteinuria grade 3, yes (%) 10 (76.9) 11 (40.7) 0.0283
 Treatment continuation, yes (%) 8 (61.5) 11 (40.7) 0.2161
 Treatment termination due to renal problem, yes (%) 2 (15.4) 5 (18.5) 0.8053